Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis.
OBJECTIVE
Since 1980, we have performed plasmapheresis before thymectomy for patients with generalized symptoms in order to protect against myasthenic crisis and to improve patient outcomes after thymectomy. The aim of this study was to evaluate an immediate and a long-term results of plasmapheresis before thymectomy for myasthenia gravis, retrospectively.


METHODS
Between January 1980 and December 1997, 51 patients with Osserman class IIA or IIB symptoms were treated with transsternal thymectomy. Nineteen patients (group 1) were treated with plasmapheresis before thymectomy and 32 patients (group 2) were treated with thymectomy alone.


RESULTS
In group 1, the time of plasmapheresis prior to thymectomy was 3.2 +/- 1.5. Nine (28.1%) patients in group 2 had crisis within 1 year after thymectomy as compared with only one (5.3%) patient in group 1 had crisis (p = 0.049). There was no evidence of crisis within 30 days after thymectomy in group 1 and 5 (15.6%) patients in group 2 (p = 0.0724). There was no postoperative death among patients in group 1. Responses to thymectomy in group 1 improved significantly, the improvement and pharmacologic remission rate had increased up to 100% and 79% at 5-7 years after operation, while the improvement and pharmacologic remission rate of group 2 had increased to 81.3% (p = 0.0466 vs. group 1) and 50.0% at that time (p = 0.0427 vs. group 1).


CONCLUSIONS
The present study demonstrated that preoperative plasmapheresis may facilitate improved outcomes of patients with myasthenia gravis after thymectomy.
Nagayasu
Takeshi
T
Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yamayoshi
Takatomo
T
Matsumoto
Keitaro
K
Ide
Noboru
N
Hashizume
Satoshi
S
Nomura
Masahito
M
Muraoka
Masashi
M
Tagawa
Tsutomu
T
Akamine
Shinji
S
Oka
Tadayuki
T
D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000473:pathology / Q000628:therapy*; D010956:Plasmapheresis; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology*; D012189:Retrospective Studies; D013934:Thymectomy; D016896:Treatment Outcome
Ther Apher. 1997 Nov;1(4):343-7
10225728
Ann Thorac Surg. 1996 Sep;62(3):853-9
8784019
Arch Intern Med. 1986 Jul;146(7):1365-8
3718134
Ann Thorac Surg. 1999 Jun;67(6):1568-71
10391256
Tohoku J Exp Med. 1993 Jan;169(1):77-86
8211972
Ann Surg. 1987 Jul;206(1):79-88
3606235
N Engl J Med. 1984 Mar 22;310(12):762-71
6199669
Ann N Y Acad Sci. 1981;377:670-7
6951491
Immunol Today. 1990 Dec;11(12):450-6; discussion 456-7
2073317
Arch Surg. 1993 Aug;128(8):855-62
8343058
Lancet. 1977 Feb 19;1(8008):428-9
65541
J Clin Apher. 1999;14(1):1-8
10355656
Ann Thorac Surg. 1994 Jan;57(1):194-7
8279889
South Med J. 1985 Oct;78(10):1208-10
4049040
Lancet. 1979 Mar 3;1(8114):464-8
85055
Crit Care Med. 1993 Jun;21(6):821-2
8504646
Acta Neurol Scand. 1989 Oct;80(4):324-6
2816289
Ann Thorac Surg. 1986 Feb;41(2):189-92
3753841
Lancet. 1977 Jan 22;1(8004):190-1
64714
Neurology. 1987 Aug;37(8):1329-33
3112609
Ann Neurol. 1991 Oct;30(4):550-7
1665051
Lancet. 1979 Sep 22;2(8143):629
90282
Arch Neurol. 1979 Feb;36(2):103-6
420618
Crit Care Med. 1997 Jul;25(7):1228-35
9233752